CBIO: Crescent Biopharma Inc Financial Statements
Balance sheet, income statement, and cash flow statements for Crescent Biopharma Inc (CBIO).
$16.06M Market Cap.
CBIO Market Cap. (MRY)
CBIO Shares Outstanding (MRY)
CBIO Assets (MRY)
Total Assets
$35.62M
Total Liabilities
$47.10M
Total Investments
$0
CBIO Income (MRY)
Revenue
$0
Net Income
-$37.88M
Operating Expense
$40.04M
CBIO Cash Flow (MRY)
CF Operations
-$31.10M
CF Investing
$20.03K
CF Financing
$5.40K
CBIO Balance Sheet (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total Assets | $35,617,000 (-21.40%) | $45,316,475 (-12.53%) | $51,810,589 (-45.08%) | $94,346,648 (-33.95%) |
Assets Current | $34,804,000 (-20.52%) | $43,790,734 (-13.65%) | $50,714,705 (-44.14%) | $90,788,694 (-34.34%) |
Assets Non-Current | $813,000 (-46.71%) | $1,525,741 (39.22%) | $1,095,884 (-69.20%) | $3,557,954 (-21.95%) |
Goodwill & Intangible Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Shareholders Equity | -$15,479,000 (-140.29%) | $38,414,401 (-10.52%) | $42,929,837 (-47.39%) | $81,603,651 (-36.36%) |
Property Plant & Equipment Net | $0 (0%) | $767,828 (2.22%) | $751,174 (-61.38%) | $1,945,027 (-33.98%) |
Cash & Equivalents | $34,766,000 (-16.81%) | $41,792,830 (-12.70%) | $47,870,619 (-46.99%) | $90,307,210 (-34.12%) |
Accumulated Other Comprehensive Income | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Deferred Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Investments | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Investments Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Investments Non-Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Inventory | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Trade & Non-Trade Receivables | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Trade & Non-Trade Payables | $107,000 (-87.67%) | $868,115 (-10.52%) | $970,191 (-53.97%) | $2,107,615 (0.85%) |
Accumulated Retained Earnings (Deficit) | -$17,867,000 (96.09%) | -$456,485,212 (-8.79%) | -$419,585,792 (-12.52%) | -$372,896,990 (-20.50%) |
Tax Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Tax Liabilities | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Debt | $37,482,000 (4536.55%) | $808,402 (-11.99%) | $918,555 (-52.16%) | $1,920,014 (-31.88%) |
Debt Current | $0 (0%) | $741,558 (-19.27%) | $918,555 (-8.27%) | $1,001,407 (11.45%) |
Debt Non-Current | $37,482,000 (55973.84%) | $66,844 (0%) | $0 (0%) | $918,607 (-52.16%) |
Total Liabilities | $47,096,000 (582.35%) | $6,902,074 (-22.28%) | $8,880,752 (-30.31%) | $12,742,997 (-12.80%) |
Liabilities Current | $9,614,000 (40.65%) | $6,835,230 (-23.03%) | $8,880,752 (-24.89%) | $11,824,390 (-4.86%) |
Liabilities Non-Current | $37,482,000 (55973.84%) | $66,844 (0%) | $0 (0%) | $918,607 (-57.95%) |
CBIO Income Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Revenues | $0 (0%) | $10,000 (-86.67%) | $75,000 (-93.53%) | $1,159,767 (-88.59%) |
Cost of Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Selling General & Administrative Expense | $18,249,318 (-5.02%) | $19,213,637 (0.66%) | $19,087,443 (11.52%) | $17,115,405 (2.22%) |
Research & Development Expense | $14,259,756 (-28.96%) | $20,071,656 (-29.30%) | $28,390,879 (-40.22%) | $47,491,567 (5.70%) |
Operating Expenses | $40,039,378 (1.92%) | $39,285,293 (-17.26%) | $47,478,322 (-26.51%) | $64,606,972 (4.76%) |
Interest Expense | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Income Tax Expense | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Loss Income from Discontinued Operations | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Consolidated Income | -$37,879,158 (-2.66%) | -$36,899,420 (20.97%) | -$46,688,802 (26.39%) | -$63,427,437 (-24.30%) |
Net Income to Non-Controlling Interests | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income | -$37,879,158 (-2.66%) | -$36,899,420 (20.97%) | -$46,688,802 (26.39%) | -$63,427,437 (-24.30%) |
Preferred Dividends Income Statement Impact | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income Common Stock | -$37,879,158 (-2.66%) | -$36,899,420 (20.97%) | -$46,688,802 (26.39%) | -$63,427,437 (-24.30%) |
Weighted Average Shares | $644,772 (1.79%) | $633,425 (20.58%) | $525,312 (2.10%) | $514,532 (12.54%) |
Weighted Average Shares Diluted | $644,772 (1.79%) | $633,425 (20.58%) | $525,312 (2.10%) | $514,532 (12.54%) |
Earning Before Interest & Taxes (EBIT) | -$37,879,158 (-2.66%) | -$36,899,420 (20.97%) | -$46,688,802 (26.39%) | -$63,427,437 (-24.30%) |
Gross Profit | $0 (0%) | $10,000 (-86.67%) | $75,000 (-93.53%) | $1,159,767 (-88.59%) |
Operating Income | -$40,039,378 (-1.95%) | -$39,275,293 (17.15%) | -$47,403,322 (25.29%) | -$63,447,205 (-23.18%) |
CBIO Cash Flow Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Net Cash Flow from Investing | $20,028 (193.62%) | -$21,394 (74.59%) | -$84,191 (-463.41%) | -$14,943 (78.19%) |
Net Cash Flow from Financing | $5,398 (-99.98%) | $28,823,508 (593.30%) | $4,157,408 (-61.23%) | $10,724,346 (-40.89%) |
Net Cash Flow from Operations | -$31,098,078 (10.84%) | -$34,879,903 (24.92%) | -$46,457,488 (19.19%) | -$57,489,530 (-46.50%) |
Net Cash Flow / Change in Cash & Cash Equivalents | -$31,072,652 (-411.25%) | -$6,077,789 (85.66%) | -$42,384,271 (9.40%) | -$46,780,127 (-121.01%) |
Net Cash Flow - Business Acquisitions and Disposals | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Cash Flow - Investment Acquisitions and Disposals | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Capital Expenditure | $20,028 (193.62%) | -$21,394 (74.59%) | -$84,191 (-463.41%) | -$14,943 (78.19%) |
Issuance (Repayment) of Debt Securities | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Issuance (Purchase) of Equity Shares | $5,398 (-99.98%) | $28,823,508 (593.30%) | $4,157,408 (-61.23%) | $10,724,346 (-40.89%) |
Payment of Dividends & Other Cash Distributions | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Effect of Exchange Rate Changes on Cash | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Share Based Compensation | $4,772,921 (34.05%) | $3,560,476 (-7.70%) | $3,857,580 (-36.63%) | $6,087,286 (-11.80%) |
Depreciation Amortization & Accretion | $437,823 (-56.63%) | $1,009,539 (-2.19%) | $1,032,156 (1.83%) | $1,013,639 (6.52%) |
CBIO Financial Metrics (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Gross Margin | - | 100.00% (0.00%) | 100.00% (0.00%) | 100.00% (0.00%) |
Profit Margin | - | -368994.20% (-492.75%) | -62251.70% (-1038.26%) | -5469.00% (-989.23%) |
EBITDA Margin | - | -358898.80% (-489.56%) | -60875.50% (-1031.18%) | -5381.60% (-992.27%) |
Return on Average Equity (ROAE) | -337.70% (-361.97%) | -73.10% (15.88%) | -86.90% (-42.46%) | -61.00% (-67.58%) |
Return on Average Assets (ROAA) | -137.80% (-113.98%) | -64.40% (12.26%) | -73.40% (-34.43%) | -54.60% (-63.96%) |
Return on Sales (ROS) | - | -368994.20% (-492.75%) | -62251.70% (-1038.26%) | -5469.00% (-989.23%) |
Return on Invested Capital (ROIC) | -677.90% (-136.44%) | 1860.30% (52.07%) | 1223.30% (-39.55%) | 2023.80% (-88.83%) |
Dividend Yield | 0% (0%) | 0% (0%) | 0% (0%) | 0% (0%) |
Price to Earnings Ratio (P/E) | -0.42 (89.63%) | -4.07 (-19.54%) | -3.4 (-190.69%) | -1.17 (65.12%) |
Price to Sales Ratio (P/S) | - | 14,948.82 (604.38%) | 2,122.26 (3221.95%) | 63.89 (277.67%) |
Price to Book Ratio (P/B) | -1.04 (-126.21%) | 3.96 (6.92%) | 3.7 (305.26%) | 0.91 (-34.93%) |
Debt to Equity Ratio (D/E) | -3.04 (-1790.56%) | 0.18 (-13.04%) | 0.21 (32.69%) | 0.16 (36.84%) |
Earnings Per Share (EPS) | -59 (-1.72%) | -58 (34.83%) | -89 (27.64%) | -123 (-9.82%) |
Sales Per Share (SPS) | 0 (0%) | 0.02 (-88.81%) | 0.14 (-93.66%) | 2.25 (-89.86%) |
Free Cash Flow Per Share (FCFPS) | -48.2 (12.52%) | -55.1 (37.81%) | -88.6 (20.73%) | -111.76 (-29.99%) |
Book Value Per Share (BVPS) | -24.01 (-139.59%) | 60.65 (-25.79%) | 81.72 (-48.47%) | 158.6 (-43.45%) |
Tangible Assets Book Value Per Share (TABVPS) | 55.24 (-22.79%) | 71.54 (-27.46%) | 98.63 (-46.21%) | 183.36 (-41.30%) |
Enterprise Value Over EBIT (EV/EBIT) | 0 (0%) | -3 (-50.00%) | -2 (0%) | 0 (0%) |
Enterprise Value Over EBITDA (EV/EBITDA) | -0.05 (98.23%) | -2.88 (-21.53%) | -2.37 (-684.48%) | 0.41 (150.88%) |
Asset Turnover | 0 (0%) | 0 (0%) | 0 (-90.00%) | 0.01 (-84.85%) |
Current Ratio | 3.62 (-43.50%) | 6.41 (12.19%) | 5.71 (-25.62%) | 7.68 (-30.99%) |
Dividends | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Free Cash Flow (FCF) | -$31,078,050 (10.95%) | -$34,901,297 (25.01%) | -$46,541,679 (19.06%) | -$57,504,473 (-46.28%) |
Enterprise Value (EV) | $1,926,975 (-98.14%) | $103,519,976 (-4.46%) | $108,347,553 (527.95%) | -$25,317,625 (-163.38%) |
Earnings Before Tax (EBT) | -$37,879,158 (-2.66%) | -$36,899,420 (20.97%) | -$46,688,802 (26.39%) | -$63,427,437 (-24.30%) |
Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | -$37,441,335 (-4.32%) | -$35,889,881 (21.39%) | -$45,656,646 (26.85%) | -$62,413,798 (-24.64%) |
Invested Capital | $28,719,000 (1247.30%) | -$2,503,183 (37.77%) | -$4,022,227 (31.42%) | -$5,864,938 (-51.75%) |
Working Capital | $25,190,000 (-31.84%) | $36,955,504 (-11.66%) | $41,833,953 (-47.02%) | $78,964,304 (-37.25%) |
Tangible Asset Value | $35,617,000 (-21.40%) | $45,316,475 (-12.53%) | $51,810,589 (-45.08%) | $94,346,648 (-33.95%) |
Market Capitalization | $16,056,506 (-89.43%) | $151,968,174 (-4.33%) | $158,844,550 (113.20%) | $74,504,007 (-58.57%) |
Average Equity | $11,217,625 (-77.78%) | $50,486,064 (-5.99%) | $53,701,529 (-48.31%) | $103,894,835 (-25.89%) |
Average Assets | $27,484,718 (-52.05%) | $57,315,082 (-9.84%) | $63,570,207 (-45.28%) | $116,172,533 (-24.28%) |
Invested Capital Average | $5,587,765 (381.72%) | -$1,983,480 (48.03%) | -$3,816,678 (-21.78%) | -$3,134,091 (-1012.48%) |
Shares | 644,840 (0.14%) | 643,933 (22.83%) | 524,239 (1.32%) | 517,389 (8.18%) |
